Xilio reports 40% ORR in MSS mCRC with high plasma TMB; advances masked T cell engager programs

Xilio Therapeutics, Inc.

Vilastobart + atezolizumab: 40% ORR in heavily pre-treated MSS mCRC without liver mets and high plasma TMB (≥10 mut/Mb); p=0.05 correlation.
Estimated 55% of MSS CRC patients have high plasma TMB via Guardant360 assay, vs <10% by tissue TMB.
Preclinical masked T cell engagers show reduced systemic toxicity and enhanced durability with costimulation; PSMA candidate nominated Q3 2025.
Phase 1 efarindodekin alfa: well-tolerated at >100-fold MTD of rhIL-12, 2 PRs in advanced solid tumors, immune infiltration.
Vilastobart ctDNA data: deep reductions associated with response; 2 patients achieved endoscopic CR with undetectable ctDNA.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.